This resource has expired and is no longer an accredited course. A certificate will not be generated upon completion.
New Insights into the Treatment of Spondyloarthropathies
JOINTLY PROVIDED BY
Support for this activity has been made possible through an educational grant from AbbVie
This activity has been designed to meet the educational needs of nurses and nurse practitioners. Other healthcare providers may also participate.
In this issue of Rheumatology Nurse Practice, we will explore trends in the management of 2 of the most common spondyloarthropathies: psoriatic arthritis and ankylosing spondylitis. With the recent availability of new biologics and additional therapies on the horizon, this issue will examine how biologics and small molecule therapies are shaping the treatment of these disorders.
After participating in the activity, learners should be better able to:
- List the characteristics that differentiate the most common spondyloarthropathies
- Assess the role of pharmacologic and nonpharmacologic therapy in the treatment of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS)
- Discuss the current targets of new agents under investigation for the treatment of PsA and AS
- Analyze the efficacy and safety of specific biologic therapies commonly used to treat acute anterior uveitis
- Review the nursing-related abstracts presented at the recent American College of Rheumatology annual conference
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:
E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
DISCLOSURES AS FOLLOWS:
Sheree Carter, PhD, RN, RN-BC, No relevant financial relationships with any commercial interests.
Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Lilly, AbbVie, Celgene, Horizon, Momenta Pharmaceuticals/A; Celgene, AbbVie, Genentech, Horizon/SB.
Linda Grinnell-Merrick, MS, NP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Pfizer, GlaxoSmithKline, Horizon/A; Janssen/C, SB; AbbVie, Celgene/SB.
Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Pfizer, Crescendo/A,SB; Celgene, Sanofi/A; Antares/C; Bristol Myers-Squibb/SB.
INDEPENDENT CLINICAL PEER REVIEWER
Carrie Beach, RN, BSN, Rheumatology Nurse, Columbus (OH) Arthritis Center has disclosed the following relationships: Pfizer, Horizon and Novartis/A.
John JD Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner, American Academy of CME: No relevant financial relationships with any commercial interests.
Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Anne Jacobson, MPH, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.
OFF-LABEL PRODUCT DISCLOSURE
This activity will review off-label or investigational information of the following: Abatacept, tofacitinib, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, apremilast.
ACCREDITATION AND CREDIT DESIGNATION
American Academy of CME, Inc, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
American Academy of CME, Inc., designates this educational activity for 1.25 contact hours.
METHOD OF PARTICIPATION
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.
For any questions, please contact: CEServices@academycme.org
© 2017. This CNE-certified activity is held as copyrighted © by American Academy of CME and Rheumatology Nurses Society. Through this notice, the Academy and Rheumatology Nurses Society grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).